
Progressive fibrosing interstitial lung disease (PF-ILD) Program in Pharmaceutical Benefits Scheme 012-22042647

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of PBS subsidised nintedanib for patients
with progressive fibrosing interstitial lung disease (PF-ILD).

PF-ILD and listing dates

PF-ILD is part of a large group of lung disorders. It causes progressive
scarring (fibrosis) of the lung tissue.

Listing date is:

-   nintedanib - 1 May 2022

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, contact details,
item and restriction codes, the PBS Schedule and the Services Australia
website.

Related links

Manage work items in Processing and National Demand Allocation (PaNDA)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

Process telephone Authority approval application

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
